Cgbio Incis A South Korea Based Healthcare Provider Specializing In Regenerative Medicine And Biomaterial Technologythe Company Is Dedicated To Improving Quality Of Life Through Innovative Solutions For Spinal Disorders And Advanced Wound Managementcgbio Operates State Of The Art Facilitiesincluding Class 100 Clean Roomsand Emphasizes Research Driven Development And Global Expansion Cgbio Offers A Range Of Productsincluding Synthetic Bone Grafts And Spinal Implants For Stabilizationas Well As Negative Pressure Wound Therapy Systems And Antimicrobial Dressingsthe Company Also Provides Gmp Grade Growth Factors And Allograft Synthetic Bone Graftsrecentlycgbio Has Expanded Into Latin American Markets And Secured Significant Global Supply Deals For Aesthetic And Plastic Surgery Products With A Mission To Leverage Regenerative Medical Technology For Healthier Livescgbio Aims To Become A Global Leader In Regenerative Medicine Through Biomaterial Innovationthe Company Has Achieved Notable Milestonesincluding Reaching 100 Billion Krw In Revenue In 2023 And Being Recognized As A Hi Seoul Business In 2022
